Cantor Fitzgerald Forecasts Codexis FY2025 Earnings

Codexis, Inc. (NASDAQ:CDXS) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Codexis in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biotechnology company will earn ($0.51) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $11.00 target price on the stock. The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Separately, Benchmark reissued a “hold” rating on shares of Codexis in a research note on Monday, November 4th.

Codexis Stock Performance

Shares of Codexis stock opened at $4.87 on Thursday. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. Codexis has a 52-week low of $2.53 and a 52-week high of $6.08. The company has a fifty day moving average of $4.86 and a 200-day moving average of $3.78.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.04). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The firm had revenue of $12.83 million for the quarter, compared to the consensus estimate of $11.64 million. During the same quarter last year, the company posted ($0.26) earnings per share.

Institutional Trading of Codexis

Institutional investors and hedge funds have recently bought and sold shares of the company. Private Advisor Group LLC grew its holdings in shares of Codexis by 1.3% during the third quarter. Private Advisor Group LLC now owns 278,699 shares of the biotechnology company’s stock valued at $858,000 after buying an additional 3,458 shares during the last quarter. Rhumbline Advisers raised its position in Codexis by 3.8% in the 2nd quarter. Rhumbline Advisers now owns 108,594 shares of the biotechnology company’s stock worth $337,000 after buying an additional 4,017 shares during the last quarter. Perkins Capital Management Inc. raised its stake in Codexis by 2.8% during the 3rd quarter. Perkins Capital Management Inc. now owns 164,100 shares of the biotechnology company’s stock valued at $505,000 after buying an additional 4,500 shares during the last quarter. Algert Global LLC boosted its stake in shares of Codexis by 17.1% in the 2nd quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock worth $129,000 after buying an additional 6,069 shares during the last quarter. Finally, Empire Financial Management Company LLC grew its holdings in shares of Codexis by 4.7% in the third quarter. Empire Financial Management Company LLC now owns 222,952 shares of the biotechnology company’s stock worth $687,000 after acquiring an additional 10,000 shares during the period. 78.54% of the stock is currently owned by institutional investors.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.